CD274 and non-small cell lung carcinoma: Pembrolizumab remains the standard of care for NSCLC with PD-L1 overexpression (TPS ≥50%), with reported median objective response rates, progression-free survival, and overall survival of 44.8%, 10.3 months, and 26.3 months, respectively (15).